ArticleArthritis research & therapy2022

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.

Dafna D Gladman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.